- Met the primary endpoint, achieving statistically significant 68% (p
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
Watch Apellis Pharmaceuticals' latest callApellis Pharmaceuticals (NASDAQ:APLS) Q4 2025 Earnings Call · Replay · Feb 24Read the transcript of Apellis Pharmaceuticals (NASDAQ:APLS) Q4 2025 Earnings CallApellis Pharmaceuticals, Inc. on 6ix
Story so far
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
- Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Earlier from Apellis Pharmaceuticals
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
- Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
- Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
- SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
Later from Apellis Pharmaceuticals
- Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
- Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
- Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
- Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
- Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Follow Apellis Pharmaceuticals into a list and get an email when it puts out news.
Follow Apellis Pharmaceuticals